Sloning Further Strengthens its Intellectual Property with new U.S. Patent
News Apr 16, 2010
Sloning, a supplier of synthetic biology tools was awarded US Patent No, 7,695,906. Sloning’s enabling platform technology - Slonomics® - allows researchers to increase the success rate of their screening for new and optimized therapeutic antibodies, proteins or industrial enzymes.
Slonomics®, a patented technology that uses a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries - 'one codon at a time'. For library production, multiple codons can be introduced in parallel at any desired sequence position.
The absence of functional bias and the ability to select and control delivery of up to 20 codons at any ratio results in exceptionally high quality libraries containing the complete set of desired mutants. In addition, mutated regions of varying length can also be incorporated in the design.
“The granted patent represents another key step in the ongoing development of our technology portfolio and allows the company to focus its efforts on developing additional innovative products and services for the protein and antibody engineer” says Dr. Jan Van den Brulle, Scientific Director of Sloning R&D.
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.